FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280514344> ?p ?o ?g. }

• W4280514344 abstract "Abstract Background: Declining responsiveness to artemether-lumefantrine (AL), the ACT of choice since 2005, has been reported in Nigeria. Pyronaridine-artesunate (PA) is a newer fixed-dose ACT recently included in the WHO list of prequalified medicines for the treatment of uncomplicated falciparum malaria. However, data from the Nigerian paediatric population is scarce. Therefore, we compared the efficacy and safety of pyronaridine-artesunate with artemether-lumefantrine using the WHO 28-day antimalarial efficacy protocol in Ibadan, southwest Nigeria. Method: In an open-labelled randomized controlled clinical trial children aged 3 to 144 months with a history of fever and microscopically confirmed Plasmodium falciparum malaria were enrolled. Enrolees were randomly assigned to receive pyronaridine–artesunate or artemether–lumefantrine at standard dosages according to bodyweight, for 3 days. Venous blood was obtained for haematology, blood chemistry and liver function tests on days 0, 3, 7, and 28 as part of safety evaluation. Results: One hundred and sixty-five (95.9%; 165/172) enrolees completed the study. About half [52.3%; 90/172] of enrolees were male. Eighty-seven (50.6%) received artemether-lumefantrine while 85 (49.4%) received pyronaridine-artesunate. Day 28 adequate clinical and parasitological response for pyronaridine-artesunate was 92.7% [(76/82) 95% CI: 83.1, 95.9] and 71.1% [(59/83) 95% CI: 60.4, 79.9] for artemether-lumefantrine (ρ<0.001). PCR-corrected cure rates were similar for PA and AL as all parasite recurrences [PA = 6 (7.3%); AL = 24 (28.9%)] were re-infections. Haematological recovery at day-28 was significantly better among pyronaridine-artesunate treated patients (34.9% ± 2.8) compared to those treated with artemether-lumefantrine (33.1% ±3.0) [ρ = 0.002]. Adverse events in both treatment arms were fever, chills and rigors, anorexia, cough and headache, similar to symptoms observed during malaria infection. Blood chemistry and liver function tests were mostly within normal limits, with an occasional marginal rise. There was no serious adverse event in both arms of the study. Conclusion: The two ACTs were well-tolerated. Pyronaridine-artesunate has a higher ACPR than artemether-lumefantrine in the per-protocol-population and a non-inferiority response after PCR correction in the treatment of uncomplicated malaria in Nigerian children. The results of this study support the inclusion of pyronaridine-artesunate in the antimalaria treatment guidelines in Nigeria. Retrospective Trial Registration in Clinicaltrials.gov: NCT05192265" @default.
• W4280514344 created "2022-05-22" @default.
• W4280514344 creator A5003871340 @default.
• W4280514344 creator A5005832231 @default.
• W4280514344 creator A5038575237 @default.
• W4280514344 creator A5054381471 @default.
• W4280514344 creator A5059428502 @default.
• W4280514344 creator A5062302280 @default.
• W4280514344 creator A5072728156 @default.
• W4280514344 creator A5075745116 @default.
• W4280514344 creator A5078483356 @default.
• W4280514344 creator A5090336507 @default.
• W4280514344 date "2022-05-20" @default.
• W4280514344 modified "2023-10-18" @default.
• W4280514344 title "Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine in the Treatment of Acute Uncomplicated Malaria in Children in South-West Nigeria: An open- labelled randomized controlled trial" @default.
• W4280514344 doi "https://doi.org/10.21203/rs.3.rs-1664143/v1" @default.
• W4280514344 hasPublicationYear "2022" @default.
• W4280514344 type Work @default.
• W4280514344 citedByCount "0" @default.
• W4280514344 crossrefType "posted-content" @default.
• W4280514344 hasAuthorship W4280514344A5003871340 @default.
• W4280514344 hasAuthorship W4280514344A5005832231 @default.
• W4280514344 hasAuthorship W4280514344A5038575237 @default.
• W4280514344 hasAuthorship W4280514344A5054381471 @default.
• W4280514344 hasAuthorship W4280514344A5059428502 @default.
• W4280514344 hasAuthorship W4280514344A5062302280 @default.
• W4280514344 hasAuthorship W4280514344A5072728156 @default.
• W4280514344 hasAuthorship W4280514344A5075745116 @default.
• W4280514344 hasAuthorship W4280514344A5078483356 @default.
• W4280514344 hasAuthorship W4280514344A5090336507 @default.
• W4280514344 hasBestOaLocation W42805143441 @default.
• W4280514344 hasConcept C126322002 @default.
• W4280514344 hasConcept C168563851 @default.
• W4280514344 hasConcept C203014093 @default.
• W4280514344 hasConcept C2776120307 @default.
• W4280514344 hasConcept C2778048844 @default.
• W4280514344 hasConcept C2778059366 @default.
• W4280514344 hasConcept C2778118209 @default.
• W4280514344 hasConcept C2778371730 @default.
• W4280514344 hasConcept C2778629330 @default.
• W4280514344 hasConcept C2780780316 @default.
• W4280514344 hasConcept C2908647359 @default.
• W4280514344 hasConcept C71924100 @default.
• W4280514344 hasConcept C99454951 @default.
• W4280514344 hasConceptScore W4280514344C126322002 @default.
• W4280514344 hasConceptScore W4280514344C168563851 @default.
• W4280514344 hasConceptScore W4280514344C203014093 @default.
• W4280514344 hasConceptScore W4280514344C2776120307 @default.
• W4280514344 hasConceptScore W4280514344C2778048844 @default.
• W4280514344 hasConceptScore W4280514344C2778059366 @default.
• W4280514344 hasConceptScore W4280514344C2778118209 @default.
• W4280514344 hasConceptScore W4280514344C2778371730 @default.
• W4280514344 hasConceptScore W4280514344C2778629330 @default.
• W4280514344 hasConceptScore W4280514344C2780780316 @default.
• W4280514344 hasConceptScore W4280514344C2908647359 @default.
• W4280514344 hasConceptScore W4280514344C71924100 @default.
• W4280514344 hasConceptScore W4280514344C99454951 @default.
• W4280514344 hasLocation W42805143441 @default.
• W4280514344 hasOpenAccess W4280514344 @default.
• W4280514344 hasPrimaryLocation W42805143441 @default.
• W4280514344 hasRelatedWork W2042138153 @default.
• W4280514344 hasRelatedWork W2049209443 @default.
• W4280514344 hasRelatedWork W2069169531 @default.
• W4280514344 hasRelatedWork W2096747008 @default.
• W4280514344 hasRelatedWork W2132044754 @default.
• W4280514344 hasRelatedWork W2188213017 @default.
• W4280514344 hasRelatedWork W2286471707 @default.
• W4280514344 hasRelatedWork W2753392820 @default.
• W4280514344 hasRelatedWork W2805309778 @default.
• W4280514344 hasRelatedWork W2884255907 @default.
• W4280514344 isParatext "false" @default.
• W4280514344 isRetracted "false" @default.
• W4280514344 workType "article" @default.